MARKET

XERS

XERS

Xeris Biopharma Holdings
NASDAQ
6.23
+0.31
+5.24%
After Hours: 6.23 0 0.00% 17:36 05/20 EDT
OPEN
5.93
PREV CLOSE
5.92
HIGH
6.25
LOW
5.91
VOLUME
1.44M
TURNOVER
--
52 WEEK HIGH
10.08
52 WEEK LOW
4.300
MARKET CAP
1.08B
P/E (TTM)
112.25
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at XERS last week (0511-0515)?
Weekly Report · 2d ago
What Xeris Biopharma Holdings (XERS)'s Profit Return and Higher 2026 Guidance Means For Shareholders
Simply Wall St · 3d ago
Shareholders Will Be Pleased With The Quality of Xeris Biopharma Holdings' (NASDAQ:XERS) Earnings
Simply Wall St · 5d ago
Xeris Pharmaceuticals (XERS) Receives a Buy from Barclays
TipRanks · 6d ago
Weekly Report: what happened at XERS last week (0504-0508)?
Weekly Report · 05/11 09:30
A Look At Xeris Biopharma Holdings (XERS) Valuation After Its Profit Turnaround And Guidance Hike
Simply Wall St · 05/10 22:21
Results: Xeris Biopharma Holdings, Inc. Confounded Analyst Expectations With A Surprise Profit
Simply Wall St · 05/09 13:56
H.C. Wainwright Remains a Buy on Xeris Pharmaceuticals (XERS)
TipRanks · 05/08 10:50
More
About XERS
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company focused on improving patient lives by developing and commercializing products across a range of therapies. It has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is a therapy for primary periodic paralysis. It also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism. It is pursuing formulation and development partnerships to apply its XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies’ proprietary drugs and biologics. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.

Webull offers Xeris Biopharma Holdings Inc stock information, including NASDAQ: XERS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XERS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XERS stock methods without spending real money on the virtual paper trading platform.